Navigation Links
Anthrax inhibitor counteracts toxin, may lead to new therapeutics

Researchers from Rensselaer Polytechnic Institute and the University of Toronto have designed a nanoscale assembly of molecules that successfully counteracts and inhibits anthrax toxin in animal and laboratory experiments. The novel approach used to neutralize anthrax toxin could be applied in designing potent therapeutics for a variety of pathogens and toxins, according to the researchers.

Anthrax toxin, secreted by the anthrax bacterium, is made of proteins and toxic enzymes that bind together to inflict damage on a host organism. The inhibitor, which is described by the Rensselaer-Toronto team in the April 23 online edition of the journal Nature Biotechnology, works by preventing the assembly of toxic enzyme components, thereby blocking the formation of fully assembled anthrax toxin and neutralizing its activity.

The inhibitor protected rats from anthrax toxin in the study.

"Our eventual goal is to use the inhibitor as a human therapeutic for anthrax exposure, one that can stop the toxin from functioning inside the body," says Ravi Kane, the Merck Associate Professor of Chemical and Biological Engineering at Rensselaer and a principal investigator of the project. "Combining the inhibitor with antibiotic therapy may increase the likelihood of survival for an infected person."

The 2001 intentional release of anthrax spores via postal mail in the United States led to increased research on possible therapeutics and vaccines to treat toxins that could be used as biological weapons. The current treatment for anthrax exposure is antibiotics, but inhalation anthrax still has a fatality rate of 75 percent even after antibiotics are given, according to the Centers for Disease Control and Prevention. Antibiotics slow the progression of infection by targeting the bacteria, but do not counter the advanced destructive effects of anthrax toxin in the body.

Anthrax toxin is a polyvalent protein complex in that it displays multiple copies of
'"/>

Source:Rensselaer Polytechnic Institute


Page: 1 2 3

Related biology news :

1. Study Models Impact Of Anthrax Vaccine
2. Anthrax test, developed by army and CDC, receives FDA approval
3. Anthrax inhibitors identified by Burnham team
4. Anthrax stops body from fighting back, study shows
5. Anthrax spores may survive water treatment
6. Anthrax attack posed greater potential threat than thought
7. Anthrax paralyzes immune cells with lethal toxin, UF research shows
8. Protease inhibitors reach beyond HIV
9. UNC scientists discover new role for protein as fundamental inhibitor of cell movement
10. Small molecule inhibitor of cholera discovered
11. Enzyme inhibitors block replication of SARS virus
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Anthrax inhibitor counteracts toxin may lead new therapeutics

(Date:7/21/2015)... , July 21, 2015  NXT-ID, Inc. ... a biometric authentication company focused on the growing ... smart wallet, announces that it has filed provisional ... and Method. This invention highlights ... only authorizes an account, but also the user ...
(Date:7/13/2015)... , Jul. 13, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... provisional patent 62/188684 for BEHAVIORAL-DIRECTED AUTHENTIATION ... new convenient and secure method to make payments.  ... payment methods, introduced with its groundbreaking voice-direct payment ...
(Date:7/9/2015)... , July 9, 2015  Synaptics Inc. ... of human interface solutions, today announced a ... first fully hardware encapsulated fingerprint sensor and ... technology is literally off the grid, isolating ... matching within the fingerprint sensor to provide ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3
... people are biologically more susceptible to drug addiction than others, ... In the August 15, 2007 issue of the Journal of ... study that may help answer this question. ... had a particular receptor in the brain that is more ...
... August 15, 2007) A prominent problem in AIDS ... to concentrate and perform normal movements. Scientists at ... how HIV/AIDS disrupts the normal replication of stem cells ... forming. Drs. Stuart Lipton, Marcus Kaul, Shu-ichi Okamoto ...
... reported new insight into the pathology underlying a ... that is caused by alterations in the same ... tremor/ataxia syndrome (FXTAS) overwhelmingly affects males, usually in ... In contrast, fragile X syndrome manifests itself from ...
Cached Biology News:Nicotinic receptors may be important targets for treatment of multiple addictions 2AIDS interferes with stem cells in the brain 2AIDS interferes with stem cells in the brain 3Deep into the machinery of adult fragile X 2Deep into the machinery of adult fragile X 3
(Date:7/27/2015)... , July 27, 2015 /PRNewswire/ - Quest PharmaTech ... company developing and commercializing products for the treatment of ... Quest announces that it has closed a $1,000,000 unit ... placement of 16,666,667 units of the Company at a ... of one common share and one common share purchase ...
(Date:7/27/2015)...   Inocucor Technologies Inc ., the agriculture ... farmers, has received a notice of allowance from ... patent application to protect Inocucor consortia and unique ... yields on farms and in greenhouses. ... microbial consortium and its fermentation byproducts, which are ...
(Date:7/27/2015)... The Brain & Behavior Research ... annual Klerman and Freedman Prizes, recognizing exceptional clinical ... supported by NARSAD Young Investigator Grants. The grants ... in neurobiological and psychosocial research, garner pilot data ... detection, treatment, prevention and cure of mental illnesses. ...
(Date:7/26/2015)... ... July 26, 2015 , ... Maine ... calibration verification / linearity test kit. The VALIDATE® ANEMIA kit contains Ferritin, Folate, ... is prepared using the CLSI recommended “equal delta” method for linearity testing and ...
Breaking Biology Technology:Quest PharmaTech Closes $1,000,000 Private Placement 2Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 2Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 3Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 2Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 3Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 4Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 5Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 6Maine Standards Company, LLC Announces Release of VALIDATE® ANEMIA Calibration Verification / Linearity Test Kit 2
... YORK, March 5 Bristol-Myers Squibb,Company (NYSE: ... of Directors,has elected Jean-Marc Huet senior vice president ... this role, Mr. Huet will be,responsible for directing ... the global financial operations of the organization and ...
... projects ONOM@TOPIC and SilOnIS shared ... the most innovative and sustainable project in ... European smartcard platform for,citizenship and mobile multimedia ... secure for users,while adding value for network ...
... March 4 On Wednesday, March 5, 2008,at 8:30 a.m. Eastern/2:30 p.m. Central European/5:30 ... CTIC),management team will host a conference call to discuss the company,s recent,transactions targeting cleaning ... ... ...
Cached Biology Technology:Bristol-Myers Squibb Board Elects Jean-Marc Huet Senior Vice President and Chief Financial Officer 2Bristol-Myers Squibb Board Elects Jean-Marc Huet Senior Vice President and Chief Financial Officer 3MEDEA+ Noblanc award highlights improvements in microelectronics 2MEDEA+ Noblanc award highlights improvements in microelectronics 3Cell Therapeutics, Inc. to Hold Conference Call to Update on Recent Transactions and Upcoming Milestones 2